7.57
0.36 (4.99%)
| Previous Close | 7.21 |
| Open | 7.20 |
| Volume | 264,506 |
| Avg. Volume (3M) | 304,068 |
| Market Cap | 507,011,936 |
| Price / Earnings (TTM) | 47.31 |
| Price / Earnings (Forward) | 11.51 |
| Price / Sales | 1.10 |
| Price / Book | 3.67 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -5.51% |
| Operating Margin (TTM) | 4.01% |
| Diluted EPS (TTM) | -0.480 |
| Quarterly Revenue Growth (YOY) | -4.30% |
| Total Debt/Equity (MRQ) | 197.40% |
| Current Ratio (MRQ) | 1.43 |
| Operating Cash Flow (TTM) | 25.47 M |
| Levered Free Cash Flow (TTM) | 49.52 M |
| Return on Assets (TTM) | 3.33% |
| Return on Equity (TTM) | -20.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Bioventus Inc. | Bullish | Mixed |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 11.87% |
| % Held by Institutions | 71.55% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Craig-Hallum, 111.36%) | Buy |
| Median | 15.00 (98.15%) | |
| Low | 14.00 (Barrington Research, 84.94%) | Buy |
| Average | 15.00 (98.15%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 06 Mar 2026 | 14.00 (84.94%) | Buy | 8.41 |
| 09 Feb 2026 | 13.00 (71.73%) | Buy | 8.52 | |
| Craig-Hallum | 06 Mar 2026 | 16.00 (111.36%) | Buy | 8.41 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |